Artificial intelligence is starting to transition from being software to becoming a means of scientific discovery, and the latter development did not go unnoticed in the biotech market sector last week. Shares of CRISPR Therapeutics (CRSP) fell after Anthropic revealed that its Claude AI model had independently discovered a new uncharacterized enzyme system that shows certain similarities to CRISPR.
Anthropic stated that Claude independently analyzed an extensive database of DNA sequences and discovered what it called array-associated reverse transcriptases, or ARTs. Notably, scientists still do not know what the primary function of the system is. Anthropic stated that further experiments are being carried out.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
That distinction is significant since the discovery shows how AI can accelerate biological research, but it does not constitute a commercially validated alternative to CRISPR/Cas9. What is relevant for CRSP investors is whether the decline changes anything regarding the story behind it.
About CRISPR Therapeutics Stock
Swiss company CRISPR Therapeutics is a biotech firm developing treatments using gene-editing technology. It has a market capitalization of about $5.24 billion and is primarily known for CASGEVY, which CRSP developed in collaboration with Vertex Pharmaceuticals (VRTX), making it the first treatment developed using CRISPR gene editing.
CRSP stock is down about 28% from its 52-week high of $78.48 but still up about 28% from its 52-week low of $44.12. Recently, momentum has decreased, with CRSP shares having risen by about 1% over the past five days. This performance contrasts with the broad market since the S&P 500 Index ($SPX) was up by about 12.4% year-to-date (YTD).
www.barchart.com Valuation becomes complicated since CRISPR Therapeutics is still unprofitable, which makes its trailing P/E ratio irrelevant. The company trades at a price-book ratio of about 3.1x. It has an unusually high price-sales ratio, which happens since CRSP generates very little revenue directly while the economics of CASGEVY are split with Vertex. This means that the progress of its pipeline, its commercialization, and its cash resources become more important factors than earnings multiples.
Q2 Earnings Beat
In Q2 of 2026, CRISPR Therapeutics posted a net loss of $0.94 per share, narrower than the $1.10 net loss that analysts expected before the report. Additionally, it showed quite a significant improvement over the $2.40 net loss posted in Q2 of 2025. The company's revenue reached $10.18 million, which is up quite substantially from the $892,000 of the previous quarter.
The balance sheet is yet another indispensable aspect of the company's story. CRISPR Therapeutics ended June with approximately $2.36 billion of cash, cash equivalents, and marketable securities, up from $1.98 billion as of December 2025. At the same time, its quarterly net loss fell to $91.2 million from $208.5 million in Q2 2025.
More importantly, the commercialization of CASGEVY has been progressing. In Q2, CRISPR's therapy brought in $76 million of revenues, increasing by 78% quarter-over-quarter (QoQ) and 151% year-over-year (YoY). The FDA expanded its approval to children as young as two with either sickle cell disease or transfusion-dependent beta-thalassemia, potentially adding another 5,500 patients to the group of people that will be able to receive the treatment.
Besides CASGEVY, CRSP has been expanding its pipeline with its development of such therapies as CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency. Both of the latter are undergoing phase 1 studies.
It should be noted here that, while Anthropic has made a discovery that may prove valuable in the future, it explicitly states that ART's function is still not known. Meanwhile, CRSP has already established a commercially available CRISPR-based therapy and a number of clinical-stage programs. As a result, the significance of Anthropic's discovery might not be the competition but the acceleration of AI's ability to discover new gene-editing techniques.
What Do Analysts Say About CRSP Stock?
Despite the volatility, Wall Street seems relatively optimistic about CRISPR Therapeutics with a "Moderate Buy" consensus rating. The Street-high target for CRSP stock is $291, while the street-low target is $44. The mean target of $85.06 suggests about 53% potential upside from the current stock price of $55.62. The considerable disparity between the highest and the lowest target indicates quite a lot about CRSP—there is still quite a lot of uncertainty about the ultimate commercial success of the company's pipeline. The discovery by Anthropic is an interesting development in the gene-editing landscape, especially if AI is capable of significantly shortening the process of discovery of new biological systems.
However, at the moment, the discovery is merely an uncharacterized system and not a gene-editing technique. CRSP's near-term investment thesis stays much more related to CASGEVY adoption and pipeline progress than Anthropic's discovery.
https://www.barchart.com On the date of publication, Yiannis Zourmpanos did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
Anthropic Just Made a CRISPR-Like Discovery. What It Actually Means for CRSP Stock Investors. If You Love Speculating, You Should Keep a Close Eye on Novo Nordisk Stock Google's AI Chips Are Set to Be Sent to Space. What This Means for GOOGL Stock. What You Need to Know Ahead of EQT’s Earnings Release